APA (7th ed.) Citation

Mateos, M., Hari, P., Bahlis, N., Chari, A., Donk, N. v. d., Dholaria, B., . . . Askari, E. (2022, April). B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. HemaSphere.

Chicago Style (17th ed.) Citation

Mateos, M., et al. "B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS." HemaSphere Apr. 2022.

MLA (9th ed.) Citation

Mateos, M., et al. "B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS." HemaSphere, Apr. 2022.